PMID- 30070081
OWN - NLM
STAT- MEDLINE
DCOM- 20190826
LR  - 20190826
IS  - 1899-5276 (Print)
IS  - 1899-5276 (Linking)
VI  - 28
IP  - 4
DP  - 2019 Apr
TI  - Low-density lipoprotein-decorated and Adriamycin-loaded silica nanoparticles for 
      tumor-targeted chemotherapy of colorectal cancer.
PG  - 479-487
LID - 10.17219/acem/79561 [doi]
AB  - BACKGROUND: Chemotherapy for colorectal cancer remains an unsatisfactory method 
      of treatment and requires the development of more advanced drug delivery systems 
      (DDSs). Among inorganic materials, silica nanoparticles (SLNs) have been 
      considered a suitable candidate to be developed as versatile carriers for drug 
      delivery and imaging applications. Low-density lipoprotein (LDL) is a widespread 
      material that is responsible for cholesterol transport in plasma. The concept of 
      employing LDL-modified nanoparticles for tumor-targeted drug delivery has been 
      widely adopted. OBJECTIVES: The objective of this study was to develop and test a 
      new DDS for effective chemotherapy of colorectal cancer. MATERIAL AND METHODS: We 
      successfully developed an Adriamycin (Adr)-loaded DDS based on LDL-modified SLNs 
      (LDL/SLN/Adr). The tumor-homing property of LDL and the drug-loading capability 
      of SLNs were combined to prepare LDL/SLN/Adr that can specifically deliver Adr to 
      the cancer site to achieve effective chemotherapy of HT-29 colorectal cancer. 
      RESULTS: In vitro analysis showed that LDL/SLN/Adr consisted of nano-sized 
      particles and was capable of targeting the low-density lipoprotein receptors 
      (LDLR) which were overexpressed in many cancer cell lines. As a result, 
      LDL/SLN/Adr exerted better cytotoxicity than unmodified SLNs and free drugs. In 
      vivo imaging and anticancer assays also confirmed the preferable tumor-homing and 
      enhanced anticancer effect of LDL/SLN/Adr. CONCLUSIONS: LDL/SLN/Adr might be a 
      promising DDS for effective chemotherapy of colorectal cancer.
FAU - Shi, Gang
AU  - Shi G
AD  - Department of Colorectal Surgery, Cancer Hospital of China Medical University, 
      Liaoning Cancer Hospital & Institute, Shenyang, China.
FAU - Li, Jibin
AU  - Li J
AD  - Department of Colorectal Surgery, Cancer Hospital of China Medical University, 
      Liaoning Cancer Hospital & Institute, Shenyang, China.
FAU - Yan, Xiaofei
AU  - Yan X
AD  - Department of Colorectal Surgery, Cancer Hospital of China Medical University, 
      Liaoning Cancer Hospital & Institute, Shenyang, China.
FAU - Jin, Keer
AU  - Jin K
AD  - Department of Colorectal Surgery, Cancer Hospital of China Medical University, 
      Liaoning Cancer Hospital & Institute, Shenyang, China.
FAU - Li, Wenya
AU  - Li W
AD  - Department of Colorectal Surgery, Cancer Hospital of China Medical University, 
      Liaoning Cancer Hospital & Institute, Shenyang, China.
FAU - Liu, Xin
AU  - Liu X
AD  - Department of Colorectal Surgery, Cancer Hospital of China Medical University, 
      Liaoning Cancer Hospital & Institute, Shenyang, China.
FAU - Zhao, Jianfeng
AU  - Zhao J
AD  - Department of Colorectal Surgery, Cancer Hospital of China Medical University, 
      Liaoning Cancer Hospital & Institute, Shenyang, China.
FAU - Shang, Wen
AU  - Shang W
AD  - Department of Colorectal Surgery, Cancer Hospital of China Medical University, 
      Liaoning Cancer Hospital & Institute, Shenyang, China.
FAU - Zhang, Rui
AU  - Zhang R
AD  - Department of Colorectal Surgery, Cancer Hospital of China Medical University, 
      Liaoning Cancer Hospital & Institute, Shenyang, China.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Adv Clin Exp Med
JT  - Advances in clinical and experimental medicine : official organ Wroclaw Medical 
      University
JID - 101138582
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Drug Carriers)
RN  - 0 (Lipoproteins, LDL)
RN  - 7631-86-9 (Silicon Dioxide)
RN  - 80168379AG (Doxorubicin)
MH  - Antibiotics, Antineoplastic/*administration & dosage/therapeutic use
MH  - Cell Line, Tumor
MH  - Colorectal Neoplasms/*drug therapy
MH  - Doxorubicin/*administration & dosage/therapeutic use
MH  - *Drug Carriers
MH  - Drug Delivery Systems/*methods
MH  - Hep G2 Cells
MH  - Humans
MH  - Lipoproteins, LDL/metabolism/*pharmacology
MH  - Nanoparticles/*administration & dosage
MH  - Silicon Dioxide/*administration & dosage
OTO - NOTNLM
OT  - Adriamycin
OT  - colorectal cancer
OT  - low-density lipoprotein
OT  - silica nanoparticles
EDAT- 2018/08/03 06:00
MHDA- 2019/08/27 06:00
CRDT- 2018/08/03 06:00
PHST- 2018/08/03 06:00 [pubmed]
PHST- 2019/08/27 06:00 [medline]
PHST- 2018/08/03 06:00 [entrez]
AID - 10.17219/acem/79561 [doi]
PST - ppublish
SO  - Adv Clin Exp Med. 2019 Apr;28(4):479-487. doi: 10.17219/acem/79561.